Skip to main content
Clinical Trials/NCT06738342
NCT06738342
Not yet recruiting
Not Applicable

Clinical Efficacy of a Chlorhexidine-based Mouth-rinse Containing Citrus Aurantium Amara in Patients Undergoing Periodontal Surgery: a Triple-blind, Parallel-arm, Randomized Controlled Trial

University of Roma La Sapienza1 site in 1 country32 target enrollmentDecember 2024

Overview

Phase
Not Applicable
Intervention
CHX 0.09% + Citrox + HA
Conditions
Wound Healing
Sponsor
University of Roma La Sapienza
Enrollment
32
Locations
1
Primary Endpoint
Oedema
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

The primary objective of the study is the evaluation of efficacy of a mouthwash cointaining Chlorexidine (CHX) 0.09% + HA + Citrox (test group) on the quality of wound healing and the presence plaque formation and gingival inflammation in the post-surgical phase. Futhermore stains, discolorations and adverse effects will be eventually recorded. Control group will be represented by the use of a CHX 0.12% mouthwash.

Registry
clinicaltrials.gov
Start Date
December 2024
End Date
April 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University of Roma La Sapienza
Responsible Party
Principal Investigator
Principal Investigator

Andrea Pilloni MD DDS MS

Professor

University of Roma La Sapienza

Eligibility Criteria

Inclusion Criteria

  • More than 20 natural teeth excluding the third molars
  • Clinical indication for a surgical intervention for the treatment of at least one residual pocket after non-surgical therapy (pocket depth (PD) ≥5mm)
  • Have a full mouth plaque score (FMPS) \<15% before surgery;
  • Have a full mouth bleeding score (FMBS) \<15% before surgery;
  • Ability and willingness to give written informed consent;
  • Written agreement to participate in the trial.

Exclusion Criteria

  • Use of medications, such as anti-platelet or anti-coagulant agents, any other concomitant systemic disorder, cardiovascular and diabetes diseases, allergic, infectious diseases and medications affecting periodontal inflammation
  • Pregnancy or breastfeeding;
  • Use of medication affecting the healing process;
  • Assumption of systemic or local antibiotics in the 4 weeks before trial beginning;
  • Conditions of the teeth or of the site that contraindicate the surgery (severe mobility, fractures, untreated endodontic lesions, incongruous restorations);
  • Patients with previous periodontal treatment or who were undergoing a course of dental or orthodontic treatment will be also excluded.
  • Tobacco use (10 or more cigarettes per day)
  • Inability to comply with protocol
  • Uncooperative patient

Arms & Interventions

Test group

Intervention: CHX 0.09% + Citrox + HA

Control group

Intervention: CHX 0.12%

Outcomes

Primary Outcomes

Oedema

Time Frame: 1, 3, 7 an 14 days

Presence of absence will be recorded (1 or 0).

Secondary Outcomes

  • Early Healing Score(24 hours post surgery, 3, 7 and 45 days post surgery)
  • Plaque Index modified by Turesky(1,3,7 and 14 days post surgery)
  • Gingival Index modified by Trombelli(1,3,7 and 14 days post surgery)
  • Lobene Index modified(1,3,7 and 14 days post surgery)
  • Adverse effects(1,3,7 and 14 days post surgery)

Study Sites (1)

Loading locations...

Similar Trials